The transforming growth factor b (TGF-b) signaling pathway, which is activated by the TGF-b receptor complex consisting of type I and type II TGF-b receptors (TGFBR1 and TGFBR2), regulates cell growth and death. TGF-b and components of its signaling pathway, particularly TGFBR2, have been implicated as tumor suppressor genes and important antimitogenic factors in the gastrointestinal tract and liver. An in vivo approach to study these effects has been hindered by the embryonic lethality of Tgfbr2 À/À mice and poor viability of the Tgfb1 À/À mice. Consequently, we have developed a hepatocyte-specific Tgfbr2 knockout mouse, the Alb-cre Tgfbr2 flx/flx mouse, to study the physiologically relevant effects of TGF-b signaling on epithelial cell proliferation in vivo. After 70% hepatectomy, we observed increased proliferation and an increased liver mass : body weight ratio in the Alb-cre Tgfbr2 flx/flx mice compared to Tgfbr2 flx/flx mice. We also observed decreased expression and increased phosphorylation of p130 in the livers from the Alb-cre Tgfbr2 flx/flx mice as well as increased expression of cyclin E, which is transcriptionally regulated, in part, by p130:E2F4. Consistent with these results, in a hepatocyte cell line derived from the Tgfbr2 flx/flx mice, we found that TGF-b increases the nuclear localization of E2F4, and presumably the transcriptional repression of the p130:E2F4 complex. Thus, we have demonstrated that TGF-b signaling in vivo regulates the mitogenic response in the regenerating liver, affecting the liver mass : body weight ratio after partial hepatectomy, and that these mitogenic responses are accompanied by alterations in p130 expression and phosphorylation, implicating p130 as one of the proteins regulated in vivo by TGF-b during liver regeneration.
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Introduction
The TGF-b signaling pathway has been shown to affect normal growth and development of different organ systems and to be commonly inactivated in many cancers. TGF-b exerts its effects through a heteromeric receptor complex that consists of the membraneassociated serine-threonine kinases, TGF-b receptor type I (TGFBRI), and TGF-b receptor type II (TGFBR2). Both TGFBR1 and TGFBR2 are essential for TGF-b ligand-induced effects on the cell (Lin et al., 1992; Henis et al., 1994) . Stimulation of the TGF-b pathway can cause a variety of different effects including regulation of the cell cycle, resulting in G1/S phase arrest, modulation of differentiation, induction of apoptosis, stimulation of connective tissue deposition, secondary induction of angiogenesis, and possibly maintenance of genomic stability (Chen et al., 2002; Wakefield and Roberts, 2002) . Increases or decreases in the production of TGF-b have been linked to numerous disease states, including cancer and fibrotic diseases of the kidney, liver, and lung. Furthermore, altered expression and mutations of the genes for TGF-b, the TGF-b receptors, and intracellular effectors of TGF-b signaling, the SMAD proteins, are important in the pathogenesis of certain diseases, particularly cancers of the colon, liver, and pancreas (reviewed in Blobe et al., 2000) . In fact, loss of the TGF-b receptors, TGFBR2 and TGFBR1, is a common event in human liver cancer, implicating disruption of the TGF-b signaling pathway in liver carcinogenesis (Shirai et al., 1994; Bedossa et al., 1995; Kiss et al., 1997; Salvucci et al., 1999) . It has also been shown that impairment of TGFBR2 function can enhance DEN-induced liver cancer formation in the Tgfbr2
and CRP/DkTbRII (dominant-negative TGFBR2) mouse models (Im et al., 2001; Kanzler et al., 2001) .
One of the prominent effects of TGF-b on epithelial cells is to suppress proliferation by blocking progression of cells from G1 into S phase of the cell cycle (Tucker et al., 1984; Moses et al., 1990; Howe et al., 1991; Herrera et al., 1996) . In cultured hepatocytes, the principal parenchymal cell of the liver, TGF-b, is a potent inhibitor of mitogen-stimulated DNA synthesis, both in rodent and human cells (Carr et al., 1986; McMahon et al., 1986; Strain et al., 1986; Russell, 1988a) . This growth-inhibitory effect is believed to be an important component of the tumor suppressor effects of the TGF-b signaling pathway. The pocket proteins (Rb, p107, and p130) and E2F1 and E2F4 have been implicated in TGF-b-induced cell cycle arrest (Herrera et al., 1996; Bouzahzah et al., 2000; Tedesco et al., 2002; Yagi et al., 2002) . Studies of primary hepatocyte cultures have shown that TGF-b can decrease the phosphorylation of p130 and enhance the transcriptional repression caused by p130:E2F complexes (Bouzahzah et al., 2000) . Other proposed mechanisms through which TGF-b can mediate growth inhibition include suppression of c-myc, cyclins A and D, cdk4, cdk2, and Cdc25 and induction of cdk inhibitors p15, p21 Waf1, Cip1 , and p27
Kip1 (Pietenpol et al., 1990; Ewen et al., 1993; Hannon and Beach, 1994; Polyak et al., 1994; Satterwhite et al., 1994; Alexandrow and Moses, 1995; Datto et al., 1995; Ko et al., 1995; Reynisdottir et al., 1995; Massague, 1997, 1999; Cipriano and Chen, 1998; Moustakas and Kardassis, 1998) . Importantly, TGF-b's effects on different regulators of G1 and G1/S progression vary from one cell type to another, suggesting the possibility of more than one pathway and/or mechanism for TGF-b-induced G1 arrest (Alexandrow and Moses, 1995; Bhowmick et al., 2003) .
A major deficit in our current understanding of TGFb-mediated effects on cell proliferation arises from a paucity of data showing whether these effects operate in vivo as well as in vitro. Indeed, recent studies have shown important differences in TGF-b signaling between whole animal studies and in vitro studies, which has led to our development and use of an in vivo model system (Ewen et al., 1993; Sandhu et al., 1997; Tang et al., 1998) . In the liver, TGF-b signaling through the TGFBR1-TGFBR2 receptor complex has been implicated in the regulation of biological processes to appropriately suppress the regenerative response after partial hepatectomy, after CCl 4 exposure, and after mitogen exposure (GraslKraupp et al., 1998; Nagoshi et al., 1998; Russell, 1988b) . For instance, Nagoshi et al. (1998) observed massive increases in TGF-b during involution of hyperplastic rat liver, suggesting that TGF-b helps restore the liver to its appropriate mass after mitogenic stimulation. Furthermore, Russell et al showed that the exogenous administration of TGF-b just prior to the G 1 /S boundary inhibited hepatocyte proliferation after partial hepatectomy. Repeated administration of TGF-b did not prevent liver regeneration, but did appear to delay the onset and completion of proliferation (Russell et al., 1988) . Alterations in the expression of TGF-b, in mechanisms that activate TGF-b, in TGF-b receptor expression, and in proteins that affect TGF-b-mediated transcription have all been observed during liver regeneration, suggesting a complex regulation of TGFb-mediated effects on hepatocytes and nonhepatocytes after partial hepatectomy (Braun et al., 1988; Oberhammer et al., 1996; Michalopoulos and DeFrances, 1997; Grasl-Kraupp et al., 1998; Akita et al., 2002) . Given the complexity of TGF-b signaling in the liver, we have generated a hepatocyte-specific Tgfbr2 null mouse model to determine the physiologically relevant role of TGFBR2 and TGF-b signaling in hepatocytes in the regulation of liver proliferation. Through the use of this model, we have demonstrated that loss of TGFBR2 in hepatocytes results in an increased mitogenic response and increased liver mass after partial hepatectomy, and that these mitogenic responses are accompanied by alterations in p130 expression and phosphorylation, implicating p130 as one of the proteins regulated by TGF-b during liver regeneration.
Results
Hepatocytes from Alb-cre Tgfbr2 flx/flx mice have recombined Tgfbr2 flx in the majority of hepatocytes in the liver In order to demonstrate that Alb-cre Tgfbr2 flx/flx mice are a valid in vivo model for assessing TGF-b signaling inactivation in hepatocytes, the mice were initially assessed for the efficiency of cre-induced DNA recombination of the Tgfbr2 flx allele and for loss of TGF-b responsiveness in the hepatocytes. Recombination of the Tgfbr2 flx allele was assessed using a PCR-based strategy as well as by Southern blotting (Figure 1 a-d) . Both techniques demonstrated recombination of the Tgfbr2 flx alleles, and Southern blotting revealed that the majority of the cells in the liver had undergone recombination of the locus. We further characterized the histologic pattern of recombination driven by the Alb-cre allele by crossing these mice to Gt(ROSA)26Sor tm1Sor/tm1Sor (R26R) mice to produce bigenic Alb-cre;R26R mice (Soriano, 1999) . The R26R line has a lacZ gene that is only expressed when an upstream stop cassette is excised by cre-mediated recombination. Thus, any cell that produces cre activity at a sufficiently high level, and all the cells that descend from that cell, will produce the bgalactosidase protein and can be detected by staining for b-galactosidase activity using 5-bromo-4-chloro-3-indoxyl-b-D-galactopyranoside (X-gal). In situ analysis using the Alb-cre; R26R mice at 5 weeks of age revealed that Alb-cre induces recombination of the target locus in nearly all of the hepatocytes (Figure 1e) . Tgfbr2 flx/flx hepatocytes demonstrated a >7 fold induction in 3TP-Lux activity after TGF-b treatment, whereas the Alb-cre Tgfbr2 flx/flx hepatocytes showed no TGF-b-mediated increase in 3TP-Lux activity, consistent with inactivation of TGFBR2 and TGF-b signaling in these cells (Figure 2a) .
In addition to studies of the cultured primary hepatocytes, we generated a conditionally immortalized, TGF-b-sensitive hepatocyte cell line derived from the Tgfbr2 flx/flx mice to assess the effect of TGF-b on proteins involved in the regulation of cellular proliferation. This cell line, named FIT2, was derived from hepatocytes from a H-2Kb-tsA58 (Immorto mouse) Â Tgfbr2 flx/flx mouse and demonstrates TGF-b-mediated inhibition of DNA replication, which is also seen in primary cultured hepatocytes (Figure 2b ). In addition, assessment of albumin production by the FIT2 cells confirmed that these cells maintain their differentiation state in culture and behave as primary hepatocytes (Figure 2c ).
The Alb-cre Tgfbr2 flx/flx mice have an increased mitogenic response after partial hepatectomy Interestingly, we did not observe any dramatic abnormalities of the gross or histological appearance of the livers of the Alb-cre Tgfbr2 flx/flx mice in the basal physiologic state. In light of prior studies demonstrating changes in TGFBR2 expression in the liver during compensatory hyperplasia, we next studied the effect of inactivation of TGF-b signaling on hepatocytes during liver regeneration. We subjected Alb-cre Tgfbr2 flx/flx mice and Tgfbr2 flx/flx mice to 70% hepatectomy and then killed them at serial time points after the hepatectomy. The livers were subjected to immunostaining for BrdU, which was injected 2 h prior to killing, and the nuclear labeling index was then determined for each timepoint. An increase in hepatocyte labeling was observed in the Alb-cre Tgfbr2 flx/flx compared to the Tgfbr2 flx/flx mice, with statistically significant differences detected at 24, 96 h and 1 week after partial hepatectomy (Po0.05, Mann-Whitney U-test). The hepatocyte nuclear labeling index returned to the baseline state by 1 week in the Tgfbr2 flx/flx mice, but was still increased in the Alb-cre Tgfbr2 flx/flx mice at this time. By 1 month, there was no difference between the two groups, and both groups were close to the baseline proliferation state (Figure 3a and b). Proliferation of nonhepatocytes was also assessed at these time points, and these cells showed increased proliferation after partial hepatectomy, with the maximal labeling indices occurring at 96 h. No significant difference was observed in the proliferation of nonhepatocytes between the Alb-cre Tgfbr2 flx/flx mice and Tgfbr2 flx/flx mice, although there was a nonsignificant increase in proliferation at 96 h in the Alb-cre Tgfbr2 flx/flx mice (data not shown). These results are consistent with TGFBR2 acting to inhibit hepatocyte proliferation through a cell autonomous mechanism during liver regeneration.
The cellularity of the regenerating livers was also assessed to determine if there was a difference in the process of compensatory hyperplasia between the Albcre Tgfbr2 flx/flx mice and Tgfbr2 flx/flx mice. No significant effect of loss of TGFBR2 on the cellularity in the regenerating livers, as measured by DNA concentration, was noted (data not shown).
The Alb-cre Tgfbr2 flx/flx mice have an increased liver mass : body weight ratio at 1 week and 1 month after partial hepatectomy
The livers and mice were weighed at the time of killing after the partial hepatectomy. No difference in the liver : body mass ratio was observed between the Alb-cre Tgfbr2 flx/flx mice and Tgfbr2 flx/flx mice before partial hepatectomy and for the first 96 h of regeneration. The liver mass : body weight ratio was increased in the Albcre Tgfbr2 flx/flx mice as compared to the Tgfbr2 flx/flx mice at 1 week and 1 month after hepatectomy, consistent Smad signaling has been implicated as one of the pathways through which TGF-b mediates its growthinhibitory effects (Derynck and Zhang, 2003; Siegel and Massague, 2003) . The Smad signaling pathway is regulated predominantly by activation of the receptors for ligands of the TGF-b superfamily, which include TGF-b, activin, and the bone morphogenetic proteins (BMPs). Smad2 and Smad3 are activated by being phosphorylated by the TGF-b or activin receptors, and they translocate to the nucleus after being phosphorylated. Consequently, we assessed the activation of the Smad signaling pathway after partial hepatectomy by assessing the phosphorylation status of Smad2 and the nuclear localization status of Smad2 and Smad3.
Immunostaining of the livers for Smad2 and Smad3 revealed that for Smad2 the Alb-cre Tgfbr2 flx/flx mice consistently had approximately one-half the proportion of hepatocytes showing nuclear localization compared to the Tgfbr2 flx/flx mice until 1 month after the partial hepatectomy. The greatest difference in nuclear immunostaining for Smad2 was present at 96 h and 1 week after the partial hepatectomy, which is the timepoint that showed the largest difference in proliferation between the Tgfbr2 flx/flx and Alb-cre Tgfbr2 flx/flx mice. The mean percentage of hepatocytes with nuclear Smad2 in the Alb-cre Tgfbr2 flx/flx mice was 25 vs 70% in the Tgfbr2 flx/flx mice at 96 h and 15 vs 28% at 1 week after partial hepatectomy (Po0.05) (Figure 5a ). We did not observe a substantial difference in the amount of nuclear Smad3 after partial hepatectomy between the Alb-cre Tgfbr2 flx/flx mice and Tgfbr2 flx/flx mice ( Figure 5b ). Interestingly, we observed phosphorylated Smad2 increased in both the Alb-cre Tgfbr2 flx/flx mice and Tgfbr2 flx/flx mice starting at 24 h post-hepatectomy and lasting until at least 1 week after hepatectomy. There was a modest reduction in phosphorylated Smad2 in the Alb-cre flx/flx mice is consistent with the loss of TGF-b signaling in these mice affecting the degree of Smad pathway activation occurring during liver regeneration. The presence of nuclear Smad3 and Smad2 as well as phosphorylated Smad2 in the Alb-Cre Tgfbr2 flx/flx mice, despite the lack of a functional TGF-b receptor, is most likely a result of activin signaling in these mice (Oe et al., 2004) .
Effect of TGFBR2 inactivation on TGF-b1 expression after partial hepatectomy
In order to determine whether the difference in proliferation we observed between the Alb-cre Tgfbr2 flx/flx mice and Tgfbr2 flx/flx mice was a consequence of alterations in the production of TGF-b1 in the liver, we assessed the mRNA expression of Tgfb1 after partial hepatectomy ( Figure 6 ). We observed decreased Tgfb1 expression compared to the baseline state in both the Alb-cre Tgfbr2 flx/flx mice and Tgfbr2 flx/flx mice, and found that that the Tgfbr2 flx/flx mice expressed less Tgfb1 than the Alb-cre Tgfbr2 flx/flx mice. This difference was greatest at 24 and 48 h post hepatectomy (P ¼ 0.0007 and 0.0121, respectively), and was no longer apparent by 1 week after hepatectomy. Thus, decreased Tgfb1 expression does not appear to associate with the increased proliferation observed in the Alb-cre Tgfbr2 flx/flx mice after partial hepatectomy.
Increased hepatocyte proliferation in the Alb-cre Tgfbr2 flx/flx mouse livers is associated with decreased p130 expression and increased p130 phosphorylation After identifying a difference in proliferation during liver regeneration between the Alb-cre Tgfbr2 flx/flx mice and Tgfbr2 flx/flx mice, we assessed the regulation of Rb and its cognate proteins, p107 and p130, in the regenerating livers (Bouzahzah et al., 2000) . Western blot analysis performed on pooled liver lysates harvested from mice (N ¼ 5 mice/pooled sample) at the designated time points revealed decreased p130 expression in the Alb-cre Tgfbr2 flx/flx mice at 48 and 96 h, 1 week, and 1 month after hepatectomy. In addition, a modest increase in the proportion of phosphorylated p130 relative to hypophosphorylated p130 was present at 0, 24, 36 h, 1 week, and 1 month after partial hepatectomy in the Albcre Tgfbr2 flx/flx mice (Figure 7a-c) . Assessment of p130/ Rb2 mRNA expression revealed substantially decreased p130/Rb2 expression after partial hepatectomy, as expected after release from quiescence, and, unexpectedly, increased p130/Rb2 expression in the Alb-cre Tgfbr2 flx/flx mice compared to the Tgfbr2 flx/flx mice at 24 h. Thus, these results did not show a difference between the Alb-cre Tgfbr2 flx/flx mice and Tgfbr2 flx/flx mice that would explain the decreased p130 protein expression observed in the Alb-cre Tgfbr2 flx/flx mice and suggest that the TGF-b-dependent mechanisms that regulate p130 affect protein translation or stability rather than mRNA expression (Figure 7d ). Decreased p130 protein levels would be predicted to decrease transcriptional repression mediated by p130 by affecting the E2F4-p130 complex. Consistent with this model, we found that the TGF-b-responsive FIT2 hepatocyte cell line showed concurrent decreased phosphorylated p130 and increased cytoplasmic localization of E2F4 (Figure 8 ).
We also assessed the expression and phosphorylation status of Rb and expression of p107 in these mice, and found no consistent effect on Rb or p107 expression and, unexpectedly, decreased phosphorylation of Rb on threonine 821 and serine 249/threonine 252 in the Albcre Tgfbr2 flx/flx mice, which are sites whose phosphorylation is catalysed by cdk2 and cdk4, respectively ( Figure 9 ) (Rb expression data not shown). In in vitro systems, TGF-b has been shown to effect the formation and cellular localization of p107 and E2F4 complexes as well as to suppress the phosphorylation of Rb in part by inducing inhibitors of cdk2 and cdk4 (Reynisdottir et al., 1995; Chen et al., 2002; Ten Dijke et al., 2002) . Thus, our results suggest that TGF-b-mediated regulation of some genes in vivo may differ from those observed when TGF-b acts in vitro. In light of the alterations in p130 expression observed in the Alb-cre Tgfbr2 flx/flx mice, the expression of representative genes known to be transcriptionally regulated by p130 were assessed. Cyclin A, cyclin E, and c-myc were Figure 4 Liver mass : body weight ratio after partial hepatectomy. The mice were subjected to 70% hepatectomy and then assessed at serial timepoints after the resection. A stable liver mass : body weight ratio is achieved in both the Alb-cre Tgfbr2 flx/flx mice and Tgfbr2 flx/flx mice by 1 week, but the Alb-cre Tgfbr2 flx/flx mice have a higher liver mass : body weight ratio than the Tgfbr2 flx/flx mice. This difference is maintained to at least 1 month after 70% hepatectomy TGF-b signaling and liver regeneration J Romero-Gallo et al assessed. The only change found to correlate with the changes in both proliferation and p130 expression and phosphorylation was increased expression of cyclin E1 at 96 h and 1 week in the Alb-cre Tgfbr2 flx/flx mice ( Figure  10a) . Interestingly, at the baseline state, cyclin E1 is decreased in the Alb-cre Tgfbr2 flx/flx mice compared to the Tgfbr2 flx/flx mice. The RNA expression of cyclin E1 in regenerating livers of the Alb-cre Tgfbr2 flx/flx mice and Tgfbr2 flx/flx mice was also assessed using quantitative RT-PCR (Figure 10b ). The mRNA expression of Ccne1, the gene for cyclin E1, was greater in the Albcre Tgfbr2 flx/flx mice than in Tgfbr2 flx/flx mice at 48 and 96 h. At 96 h, there was a sixfold increase in expression in the Alb-cre Tgfbr2 flx/flx mice. There was no difference in Ccne1 mRNA levels between the control group and Alb-cre Tgfbr2 flx/flx mice at the other time points, suggesting that there are additional mechanisms affected by TGF-b signaling that can regulate cyclin E1 protein levels.
Discussion
Our studies have demonstrated that the Alb-cre Tgfbr2 flx/flx mouse is an in vivo model system for studying the effect of loss of TGF-b signaling in the hepatocyte compartment of the liver. We have shown that the vast majority of the hepatocytes in these mice have undergone cre-mediated recombination of the Tgfbr2 flx allele and do not respond to TGF-b. Furthermore, we have used this mouse model to demonstrate that inactivation The liver's proliferative response after surgical removal of tissue via partial hepatectomy has led to an intense interest in determining the mitogenic and antimitogenic factors that regulate this process (Fausto and Webber, 1993; Michalopoulos and DeFrances, 1997) . The compensatory hyperplasia that occurs in this setting is an example of precisely controlled proliferation of epithelial cells in vivo, and it presents a unique opportunity to study cell proliferation in vivo. In mice, a large population of hepatocytes enters the cell cycle in a relatively synchronized fashion in the first 24-48 h after partial hepatectomy. This resulting hyperplasia is regulated by a variety of cytokines, including TNF-a, IL-6, and HGF, which play different roles in priming, initiating, or promoting the regenerative process (Webber et al., 1998; Fausto, 2000; Li et al., 2001) . As with any tightly controlled system, other substances, such as TGF-b and activin, counteract these mitogenic factors to precisely regulate proliferation after partial hepatectomy.
Activin and TGF-b have been shown to be antimitogenic cytokines for hepatocytes, but it is unclear if they , 1997) . Indeed, although it has been shown that TGF-b1 expression increases after partial hepatectomy, with a peak level occurring 24-48 h after operation, this increase in TGF-b is accompanied by downregulation of the TGF-b receptors and by increases in SnoN and Ski, which antagonize TGF-b signaling (Bissell et al., 1995; Chari et al., 1995; Scotte et al., 1997; Enami et al., 2001; Macias-Silva et al., 2002) . The changes in the expression of the TGF-b receptor, SnoN, and Ski are believed to contribute to resistance to TGF-b in the immediate post-hepatectomy state, and to promote the increase in hepatocyte proliferation after partial hepatectomy. Eventually, type I and type II TGF-b receptor expression increases and a subsequent reduction in hepatocyte proliferation occurs, consistent with TGF-b signaling acting to suppress the proliferative response (Grasl-Kraupp et al., 1998) . Furthermore, the intravenous administration of TGFb1 or a neutralizing TGF-b antibody can delay or prolong the proliferative response, respectively (Russell et al., 1988; Enami et al., 2001 ). Thus, these prior studies have provided substantial indirect data that suggest that TGF-b is one of the physiologically regulated factors that suppresses liver proliferation. However, despite this indirect evidence, it has not been possible until recently to directly demonstrate that TGF-b suppresses liver mitogenesis in vivo because of lack of an adequate animal model. Our studies now provide direct evidence that TGF-b is a physiologically relevant factor in the suppression of hepatocyte proliferation and liver mass, and that its inhibitory activity is mediated through direct effects on the hepatocytes. The effects of TGF-b receptor inactivation on proliferation are observed both before and after the proliferative peak at 48 h, consistent with earlier studies that have shown Tgfbr2 expression and sensitivity to TGF-b nadirs during the proliferative peak of liver regeneration (Michalopoulos and DeFrances, 1997; Grasl-Kraupp et al., 1998) . Our results are also consistent with studies of liver regeneration after diethylnitrosamine treatment in which adenovirus vectors expressing dominant-negative TGBR2 were used to demonstrate that suppression of TGF-b signaling in this setting is associated with increased cell proliferation (Nakamura et al., 2000; Miyakura et al., 2001) . Finally, our results support some of the findings of Oe et al. (2004) , who used a different Alb-Cre Tgfbr2 flx/flx mouse to study liver regeneration. Interestingly, Oe et al. observed that the Alb-Cre Tgfbr2 flx/flx mice had an earlier and higher peak of DNA synthesis compared to the control mice and no increase in proliferation between Of interest, despite the loss of Tgfbr2 signaling the Alb-cre Tgfbr2 flx/flx mice, hepatocyte proliferation eventually returned to the baseline state in these mice. This is most likely a consequence of decreased expression of mitogenic cytokines, which peak around 48 h after hepatectomy, and from the effects of activin, a TGF-b superfamily member (Mead and Fausto, 1989; Michalopoulos and DeFrances, 1997; Oe et al., 2004) . Suppression of activin signaling by the administration of follistatin, a soluble antagonist of activin, or adenoviruses that express a dominant-negative activin receptor, has been shown to be associated with increased liver mitogenesis and liver mass (Kogure et al., 2000; Miyakura et al., 2001) . In fact, it is likely that the mitoinhibitory effects of TGF-b have been underestimated in our studies of the Alb-cre Tgfbr2 flx/flx mice because of the overlapping effects of activin on hepatocyte proliferation. Nonetheless, the increased proliferation and liver mass in the Alb-cre Tgfbr2 flx/flx mice suggest that TGF-b is a predominant, although not indispensable, factor in the regulation of the hepatocyte proliferation and the liver mass : body weight ratio. It also appears that TGFb regulation of Smad2, but not necessarily Smad3, may be involved in the suppression of mitogenesis after partial hepatectomy. Although Smad2 and Smad3 commonly function as a transcription factor complex with Smad4, Smad2 and Smad3 have been shown to be differentially phosphorylated and to use different nuclear import functions (Xu et al., 2000; Kurisaki et al., 2001; Liu et al., 2003) . The results from our studies suggest that Smad3 is constitutively activated either by activin or by other TGF-b-independent factors during liver regeneration and that Smad2 activation is under significant regulation by TGF-b. Furthermore, the regulation of Smad2 appears to be at the level of nuclear import rather than phosphorylation. Further studies of TGF-b-mediated regulation of Smad2 in compensatory hyperplasia in the liver are now needed to understand the mechanisms mediating these processes.
The enhanced mitogenic response observed in the Albcre Tgfbr2 flx/flx mice after partial hepatectomy led us to assess proteins that regulate cell proliferation and that have been shown to be regulated by TGF-b in vitro. Our assessment of Rb and its cognates, p107, and p130 revealed that only p130 was regulated in a direction that was consistent with the results of the cell proliferation studies. Our findings are consistent with in vivo studies in mice that overexpress TGF-b1 in the liver, which demonstrated that TGF-b can suppress the phosphorylation of p130 (Bouzahzah et al., 2000) . We observed suppressed p130 expression and a modest increase in the proportion of hyperphosphorylated p130 in the Alb-cre Tgfbr2 flx/flx mice. These effects would be predicted to lead to the increased expression of those genes normally repressed by p130/E2F4, such as Ccna, Ccne1, C-myc, or Cdc25a. Consistent with this model, we did observe increased expression of Ccne1, although not of the other candidate gene targets we assessed.
Somewhat unexpectedly and in contradiction to in vitro study results, we observed decreased rather than increased Rb phosphorylation in the Alb-cre Tgfbr2 flx/flx mice (Alexandrow and Moses, 1995) . Tang et al. (1998) observed similar discrepancies when performing studies of the Tgfb1 wt/À mouse. These differences likely reflect the effects of extracellular matrix signaling on TGF-bregulated proteins and complex effects from other paracrine and juxtacrine factors in the in vivo systems (Tang et al., 1998) . Other proteins that regulate cell proliferation were also assessed, and cyclin E expression was found to be increased at a subset of the timepoints during which increased mitogenesis was observed in the Alb-cre Tgfbr2 flx/flx mice. The cyclin E mRNA levels were elevated concurrent with decreased p130 expression and increased relative amounts of hyperphosphorylated p130 at 96 h post-hepatectomy, suggesting that cyclin E mRNA expression may be elevated through alleviation of p130 transcriptional repression. Interestingly, we did not appreciate a substantial difference in the expression of cyclin A or c-myc. Reasons for the differences between our results and those of other studies of TGF-b and cell proliferation include the following: (1) differences in TGF-b-mediated regulation of cell cycle proteins in in vivo vs in vitro contexts; (2) the role of compensatory effects vs direct effects in vivo; and (3) unintended effects of the Alb-cre transgene or Tgfbr2 flx alleles. Furthermore, there are a number of proteins that are known to interact with p130 that are altered during liver regeneration, including cyclin A, cyclin E, cdk2, histone deacetylase (HDAC) enzymes, switch/sucrose-nonfermenting chromatin remodeling (SWI/SNF) complexes, DP1, etc., and the effect of these proteins on p130-mediated transcriptional repression may explain our observations in this in vivo model system (Iwase et al., 1997; Albrecht et al., 1999; Bouzahzah et al., 2000; Tedesco et al., 2002) . It is likely that some of the increased proliferation observed in the Alb-Cre Tgfbr2 flx/flx mice during liver regeneration is due to the effects on these proteins and their ability to form functional complexes with p130.
Our observation that TGF-b signaling can suppress hepatocyte proliferation in vivo has implications for the role of TGFBR2 as a tumor suppressor gene in the liver. In light of the contextual effects of TGF-b and even possible paradoxical effects of TGF-b in carcinogenesis, there has been considerable uncertainty regarding the effect of TGF-b signaling deregulation in tumorigenesis (Wakefield and Roberts, 2002) . Indeed, studies of human hepatocellular cancer cell lines demonstrate that TGF-b can induce cell cycle arrest and apoptosis in these cells; however, studies of human hepatocellular carcinomas demonstrate increased TGF-b expression in these cancers (Fynan and Reiss, 1993; Bedossa et al., 1995) . Furthermore, Alb/Tgfb1 transgenic mice that overexpress TGF-b1 in the liver develop hepatocellular tumors at a higher frequency than wild-type mice do (Factor et al., 1997) . These mice also appear to have an increased susceptibility to carcinogen-induced cancers and show accelerated cancer formation when crossed with mice that express a C-myc transgene in the liver (Schulte-Hermann et al., 1995; Factor et al., 1997) . In contrast, recent studies of carcinogen-induced liver cancer in mice heterozygous for a Tgfbr2 null allele and in CRP/kTbRII mice, which express dominantnegative Tgfbr2 from a human CRP promoter, show that loss of functional TGFBR2 results in an increased number of tumor foci, consistent with the hypothesis that loss of TGFBR2 enhances tumor formation after carcinogen treatment (Im et al., 2001; Kanzler et al., 2001) . Furthermore, loss of TGFBR2 and TGFBR1 has been observed in preneoplastic and malignant cells from rats, mice, and humans, which supports the hypothesis that TGFBR2 and TGF-b signaling in hepatocytes act predominantly as tumor suppressors (Teramoto et al., 1998) . In light of these complex results, the Alb-cre Tgfbr2 flx/flx mouse should prove to be a useful in vivo model system to study the multifaceted role of TGF-b in the liver and of the TGF-b signaling pathway in hepatocellular carcinogenesis. Our results from studies of compensatory hyperplasia in the Alb-cre Tgfbr2 flx/flx mice suggest that TGF-b signaling on hepatocytes acts in a manner most consistent with a role as a tumor suppressor gene. Thus, our initial studies of liver regeneration with this model have informed our understanding of hepatocyte proliferation in vivo and demonstrated that animal models provide additional insight into the effects of TGF-b in the liver. The Alb-cre Tgfbr2 flx/flx mouse should prove equally useful for studying the effect of TGF-b signaling in hepatocellular carcinogenesis. The generation of the Tgfbr2 flx/flx mice has been described previously (Chytil et al., 2002) . These mice were mated with the Alb-Cre mice to achieve mice that were Tgfbr2 flx/flx /Alb-Cre (Postic et al., 1999) . Both lines of mice were maintained on the C57Bl6 genetic background and were bred to be >95% congenic. All mice were maintained in a specific pathogen-free facility in accordance with standard animal use protocols and were fed a standard chow diet.
Materials and methods

Generation and characterization of
Generation of hepatocyte cell lines
The hepatocyte cell lines were generated by Dr Robert Whitehead from H-2Kb-tsA58 (Immortomouse) Â Tgfbr2 flx/flx mice using techniques that have been previously published (Allen et al., 2000) . The cell lines were grown in a 50 : 50 mix of Hams F12 and RPMI1640 supplemented with insulin: transferrrin: selenium, 2% fetal bovine serum, and penicillin/ streptomycin (Invitrogen).
PCR conditions and primers
PCR primers and reaction conditions used for genotyping the mice and for detecting cre-induced recombination of the Tgfbr2 flx allele were used as described previously (Chytil et al., 2002) . Genotyping for the Alb-Cre allele was performed using previously published primers (kindly provided by Jeff Gordon, Washington University, St Louis, MO, USA) (Saam and Gordon, 1999; Wong et al., 2000) .
Southern blot
DNA was extracted from tails using a standard SDS buffer with proteinase K, followed by phenol : chloroform organic phase separation and ethanol precipitation. The DNA was then digested with BglIII (NEB Biolabs), subjected to agarose gel electophoresis and transferred to Hybond N (Amersham Biosciences) followed by UV crosslinking in a Stratalinker (Stratagene). The membrane was hybridized with a 500 bp genomic 32 P-labeled probe for sequences 3 0 of the insertion event using standard conditions as published previously (Chytil et al., 2002) . The membrane was then visualized using autoradiography with a Storm phosphorimager (Molecular Dynamics).
Primary hepatocyte culture
The isolated hepatocytes were obtained by harvesting livers from the Alb-cre Tgfbr2 flx/flx or Tgfbr2 flx/flx mice after perfusing the livers with HBSS and Liver Digest Media (Invitrogen) using the protocol published by Swift et al. (2001) . The viability of the isolated hepatocytes was assessed by the trypan blue-exclusion test. The cells were initially grown on type I collagen-coated culture dishes in modified DMEM (low glucose), which was changed to Williams E media after 6 h (Swift et al., 2001 ).
3TPLux luciferase reporter assay
Primary hepatocyte cultures from Alb-cre Tgfbr2 flx/flx and Tgfbr2 flx/flx mice were plated at 4 Â 10 5 per well in six-well dishes, and were then transfected with a TGF-b responsive luciferase reporter construct, 3TP-Lux, using Lipofectin (Invitrogen) (Wrana et al., 1992) . After 5 h, complete medium was added and the cells were incubated for 24 h. The cells were then treated with TGF-b (10 ng/ml) and incubated for 24 h before being lysed using passive lysis buffer from the Dual Luciferase Kit (Promega) following the manufacturer's protocol. The lysates were then assessed using the Dual Luciferase Kit (Promega) with a Monolight luminometer (BD-Pharmingen).
Partial hepatectomy
Mice between 4 and 6 weeks of age were subjected to 70% hepatectomy. They were housed and fed a standard diet prior to the procedure and were exposed to 12 h on-off light-dark cycles (lights on, 0600-1800). Given the diurnal variation observed in liver DNA synthesis after partial hepatectomy in rodents, all mice underwent partial hepatectomy or sham hepatectomy between 1100 and 1500 h (Barbiroli and Potter, 1971) . Partial hepatectomy consisted of excision of the median and left lateral lobes, which comprise approximately 70% of the total liver weight (Russell and Bucher, 1983; Coughlin et al., 1987) . Sham hepatectomy consisted of liver manipulation without ablation. Mice of each genotype, Tgfbr2 flx/flx and Alb-Cre Tgfbr2 flx/flx , were killed after partial hepatectomy at 0, 24, 36, 48, 96 , and 144 h and 1 month after hepatectomy.
Hepatic DNA content
The DNA content of the regenerating liver remnants was determined using a modification of the diphenylamine method (Richards, 1974; Russell and Bucher, 1983 ).
Preparation of cellular extracts and Western blot analysis
Livers from animals that had undergone partial hepatectomy were homogenized in TNE Lysis buffer (50 mM Tris-HCl, pH 7.6, 250 mM NaCl, 2 mM EDTA, 1 mM NaVO 3 , 1 mM NaF, 2 mM DTT, 2 mM b-mercaptenol, 5% glycerol, protease inhibitor cocktail (Roche), and phosphatases cocktail (Sigma)). The homogenates were sonicated and clarified by centrifugation for 30 min at 13 000 r.p.m. The supernatants were aliquoted and stored at À801C. Preparation of cellular fractions was carried out using the NE-PER kit following the manufacturer's protocol (Pierce Biotechnology). Protein concentration was measured using the BioRad DC protein reagent. For Western blot analysis, 6 Â Laemli sample buffer was added to 100 mg of protein extract per lane, which was then size fractionated on 7.5% SDS-PAGE or 4-15% gradient gels, transferred to PVDF membrane, and detected using the ECL Chemiluminescence kit (Amersham) or Super Signal West Pico Chemiluminescent substrate (Pierce-34080) after being incubated with the appropriate antibodies. The band intensities and relative amounts of Phospho-Smad2 and p130 were quantified using Scion Image for Windows software (NIH website). Antibodies that were used for the Western blots include the following: anti-phospho-Smad 2 rabbit polyclonal antibody: 3101 (Cell Signaling); anti-p130: sc-317; anti-p107: sc-318; anti-cyclin E: sc-481; anti-Raf1: sc-227; antibeta actin: sc-1615 (Santa Cruz Biotech); and anti-phospho Rb Ser 821: 44-582, anti-phospho Rb Ser 249/Thr 252: 44-584 (Biosource).
Smad2 and Smad3 immunostaining
Formalin-fixed, paraffin-embedded mouse liver samples and rabbit anti-Smad2 and Smad3 antibodies were used (Zymed 51-1300, 51-1500) for IHC. Three samples per variable group were selected to enable statistical analysis. Two parties calculated labeling index independently by counting stained nuclei over total nuclei per field.
BrdU immunostaining
Briefly, the mice were injected with 100 mg/kg body weight BrdU (Sigma) 2 h prior to killing. The livers from the killed animals were weighed and fixed in 4% paraformaldehyde for 6-12 h at RT, and then permeabilized with TSM (20 mM Tris, 50 mM NaCl, 3 mM MgCl 2 , and 0.5% Triton X-100). The immunostaining was performed using the In situ BrdU kit (BD Pharmingen). The nuclear labeling index was determined from counts of B1500 nuclei per liver.
Quantitative RT-PCR
RNA was isolated from pooled liver samples (N ¼ 3-5 mice/pool) using TRI reagent (Molecular Research Center).
In all, 1 mg of total RNA from each sample was reversetranscribed using oligo d(T) priming and Superscript II reverse-transcriptase (Invitrogen). TaqMan On-Demand primers and probes were used to determine the relative expression levels of Ccne1 (cyclin E gene), p130/Rb2, and Tgfb1 and 18S and b-actin in samples (Applied Biosystems: (#Mm00432367 m1 Ccne1, Mm00441724 m1 Tgfb1, Mm00487954 M1 p130, Mm00607939 S1 B-actin) for 18S RNA as a control (Applied Biosystems). The reactions were run in the ABI Prism 7700 or 7900 sequence detection system, and results were analysed by SDS 2.1 program.
Mouse albumin ELISA
FIT2 and YRII null cells (colon epithelial cells) were cultured in F-12/RPMI-based media supplemented with 10% BSA, ITS, L-glutamine and antibodies until each reached B100% confluence in T-75 flasks. The cultures were left in the same media for 48 h. Collected media were approximately five times concentrated through YM-10 columns (Microcon -42407). An ELISA kit specifically for mouse albumin was used (Bethyl Labs -E90-134). TMB/H 2 O 2 was used as substrate; the reaction was stopped with 1 N sulfuric acid, followed with 450 nm absorbance measurements. Prism 4 Software was used for quantification of mouse albumin produced by each sample.
Statistical analysis
Statistical analysis of the results was performed using either Mann Whitney U-test, Student's t-test or Fisher's exact test, as appropriate, and with the statistical package SAS version 8.02 (SAS Inc.). Potential outliers were identified using the extreme Studentized deviate method, and were excluded from the analysis when found. A P-value o0.05 was considered to be statistically significant.
